Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17090824 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL17090807 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL17090815 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL17090809 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL1494494 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL17090822 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL17090765 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL17090838 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL1494268 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 | |
| SCHEMBL1494192 | 1.00 | TSHR (0.47) | TSHRTHRBEPHX1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027672-A | 3D (three-dimensional) direct writing printing porous silicon rubber and preparation method thereof | 中国科学院化学研究所 | 2024-05-14 | — | — | CN | disclosed |
| CN-117986876-A | Organic silicon foam and preparation method thereof | 中国科学院化学研究所 | 2024-05-07 | — | — | CN | disclosed |
| CN-109415447-B | Silane-mediated enhancement of rubber storage stability | 盛禧奥欧洲有限责任公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-106146851-B | Photocurable composition and cured product containing same | 信越化学工业株式会社 | 2020-10-23 | — | — | CN | disclosed |
| US-10787562-B2 | Silane-mediated enhancement of rubber storage stability | TRINSEO EUROPE GMBH (CH) | 2020-09-29 | — | — | US | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| EP-3093303-B1 | PHOTOCURABLE COMPOSITION AND CURED PRODUCT | SHINETSU CHEMICAL CO (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-20190169406-A1 | SILANE-MEDIATED ENHANCEMENT OF RUBBER STORAGE STABILITY | TRINSEO EUROPE GMBH (CH) | 2019-06-06 | — | — | US | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-5762803-A | Silicon dioxide based microspheres for rapid chromatographic separation of biomolecules | CU CHEMIE UETIKON AG (CH) | 1998-06-09 | — | — | US | disclosed |
| WO-1998008525-A1 | PROCESS TO OBTAIN OESTROGENS FROM MARE'S URINE | SOLVAY DEUTSCHLAND GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
| EP-0693314-A1 | Silicon dioxide based adsorbents for chromatography | CU CHEMIE UETIKON AG (CH) | 1996-01-24 | — | — | EP | disclosed |
| EP-0344891-B1 | Tetraazaporphin, process for producing the same, as well as optical recording media using the same and production processes thereof | HITACHI CHEMICAL CO LTD (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-5284943-A | Containing Si, Ge or Sn | HITACHI CHEMICAL COMPANY, CO. (JP) | 1994-02-08 | — | — | US | disclosed |
| US-5217856-A | TETRAAZAPORPHIN, PROCESS FOR PRODUCING THE SAME, AS WELL AS OPTICAL RECORDING MEDIA USING THE SAME AND PRODUCTION PROCESSES THEREOF | HITACHI CHEMICAL CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0344891-A2 | Tetraazaporphin, process for producing the same, as well as optical recording media using the same and production processes thereof | Hitachi Chemical Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0101597-B1 | PROCESS FOR THE PREPARATION OF ASTAXANTHINE AND INTERMEDIATES IN THE ASTAXANTHINE SYNTHESIS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-06-22 | — | — | EP | disclosed |
| US-4585885-A | INTERMEDIATES FOR ASTAXANTHIN | HOFFMANN-LA ROCHE INC. (US) | 1986-04-29 | — | — | US | disclosed |
| EP-0101597-A2 | Process for the preparation of astaxanthine and intermediates in the astaxanthine synthesis | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | TSHR 551/4885THRB 1506/4885EPHX1 2751/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | TSHR 411/4885THRB 1249/4885EPHX1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.